Recordati to keep OTC following CVC buyout
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Recordati insists that OTC will remain a “core” part of its business following the sale of a majority stake in the company to a consortium of private-equity funds led by CVC.
You may also be interested in...
Italy's Recordati Takes Slice of French OTC Market With Laboratoires Tonipharm
Recordati's new private-equity owners make their first move to strengthen the Italian firm's position in Europe's OTC market by grabbing Paris-based Laboratoires Tonipharm and its leading Ginkor brand.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.